Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines.
Cyclooxygenase-2 (COX-2) is an important cellular target for both therapy and/or prevention of inflammatory disorders and cancer. The advent of selective COX-2 inhibitors now allows a more precise and safer treatment approach. The screening of an array of cancer cell lines for growth inhibitory effects of COX-2-selective and -nonselective inhibitors, including celecoxib (Celebrex) and rofecoxib (Vioxx), produced two unanticipated findings. Firstly, the antiproliferative effects of celecoxib were noted to be of very similar magnitude for both hematopoietic and epithelial cancer cell lines. Most hematopoietic cell lines had no detectable COX-2 expression by reverse transcription-PCR, and none expressed COX-2 protein. In addition, COX-2-negative epithelial lines were found to have IC50s for celecoxib that were very similar to their COX-2+ counterparts. Thus, important antiproliferative effects were observed that were independent of both the cell lineage and COX-2 status. Secondly, it was also observed that COX-2 inhibitor drugs, celecoxib and rofecoxib, with similar COX-2-selectivity and clinical efficacy for inflammatory indications, differed significantly in their in vitro antiproliferative effects on cancer cell lines. IC50s of 35-65 microM were observed for celecoxib across this entire panel of cell lines. Finally, no difference in the mode or degree of cytotoxicity was apparent between cell lines, because similar levels of apoptosis were observed in COX-2+ and -negative cell lines after treatment with celecoxib, with correspondingly lower levels after rofecoxib treatment. These data are important in that they provide the first direct comparison of epithelial and hematopoietic cancer cell lines, as well as a direct comparison of the in vitro anticancer effects of the two clinically available COX-2 inhibitors.
Waskewich
Chris
C
Garden State Cancer Center, Belleville, New Jersey 07109, USA.
Blumenthal
Rosalyn D
RD
Li
Honglan
H
Stein
Rhona
R
Goldenberg
David M
DM
Burton
Jack
J
D017209:Apoptosis / Q000187:drug effects; D000068579:Celecoxib; D002455:Cell Division / Q000187:drug effects; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D004354:Drug Screening Assays, Antitumor; D004847:Epithelial Cells / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D006131:Growth Inhibitors / Q000494:pharmacology; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D008565:Membrane Proteins; D011451:Prostaglandin-Endoperoxide Synthases; D011720:Pyrazoles; D013449:Sulfonamides / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D006131:Growth Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D011720:Pyrazoles; D013449:Sulfonamides; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D000068579:Celecoxib